Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PoultrySulfa is an FDA-approved veterinary antibiotic combination consisting of three sulfonamides: sulfamerazine, sulfamethazine, and sulfaquinoxaline. Developed by Huvepharma (and previously marketed by Alpharma), it is formulated as a water-soluble powder for administration via drinking water to chickens and turkeys. It is indicated for the control of coccidiosis caused by *Eimeria* species (such as *E. meleagrimitis* and *E. adenoeides*) and acute fowl cholera caused by *Pasteurella multocida*. As a sulfonamide combination, it works by inhibiting bacterial and protozoal dihydropteroate synthase, thereby blocking the synthesis of dihydrofolic acid and interfering with nucleic acid production. It is the only triple-sulfa veterinary product approved by the FDA in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on PoultrySulfa.